- 化疗耐药与TP53突变、表观遗传重塑相关。7. 总结：病理生理学与治疗靶点 MCL的病理生理学核心是Cyclin D1驱动的细胞周期失调，伴随基因组不稳定、抗凋亡信号增强和微环境支持。靶向治疗（如BTK抑制剂、BCL-2抑制剂、CDK4/6抑制剂）通过干预关键通路发挥作用，但耐药和分子异质性仍是挑战。未来的研究需聚焦于： ...
- 类型：套细胞淋巴瘤是一种罕见的侵袭性B细胞非霍奇金淋巴瘤（NHL），占NHL的3%-10%。- 起源：起源于淋巴结套区（mantle zone）的B细胞，具有独特的分子和病理特征。2. 流行病学 - 人群：多见于中老年男性（中位年龄60-70岁，男女比例约2:1）。- 发病率：年发病率约为0.5-1/10万，呈缓慢上升趋势。...
The blastoid variant of mantle cell lymphoma (MCL-BV) has an even worse clinical outcome. The mechanisms of neoplastic transformation from normal mantle cells and the relationship to the rare blastoid variant are poorly understood. BCL2 is overexpressed in indolent B-cell NHL including MCL. In ...
Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and...
7 The term, lymphomatoid papulosis, is given to cases of mantle cell lymphomas that stud along the GI tract. Mantle cell lymphoma expresses B-cell markers, CD5, CD43, and BCL-2, as well as cell-cycle markers, cyclin D1 and SOX11.7 View article Journal 2016, Radiologic Clinics of North...
- 开发针对BTK C481S突变、BCL-2耐药突变的新药。 2. 联合免疫疗法： - CAR-T联合PD-1抑制剂、双特异性抗体联合化疗。 3. 早期干预策略： - 高危患者（如TP53突变）一线使用靶向药物+化疗。 4. 表观遗传治疗： - EZH2抑制剂（如Tazemetostat）或HDAC抑制剂联合方案。 总结 套细胞淋巴瘤的治疗...
4. 弥漫大B细胞淋巴瘤（Diffuse Large B-Cell Lymphoma, DLBCL）- 相似点： - 侵袭性病程，淋巴结肿大，B症状。 - 免疫表型：部分DLBCL可表达CD5（10%-15%）。 - 关键鉴别点： - Cyclin D1：DLBCL阴性，MCL阳性。 - 遗传特征：DLBCL无t(11;14)，但可见MYC、BCL2、BCL6重排（双/三打击淋巴瘤...
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene 35, 6223–6234 (2016). Article CAS Google Scholar Beltran, E. et al. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma....
John P. Leonard, MD:One of my most memorable patients with mantle cell lymphoma is with a woman who had been through lots of therapies. She was basically on her way to hospice and was doing quite poorly. I vividly remember being in the hospital with her. As a list-ditch thing, we pu...